Semaglutide: A GLP-1 Agonist with Positive Cardiovascular Outcomes?
| Overview / Abstract: |
This application-based continuing pharmacy education course provides a journal club-focused discussion for pharamcists and student pharmacists to more adequately understand the current climate of drug approval with regard to diabetes medications. Join us as we focus on the newest GLP-1 agonist to hit the market, semaglutide, and how it compares to previously approved members of this class. Leave this session feeling confident on discussing the true cardiovascular effects of GLP-1 agonists with patients and providers in your practice. |
|
Expiration |
Oct 10, 2021 |
|
Discipline(s) |
Pharmacy CPE |
|
Format |
Online, Webinar / Webcast / Video |
|
Cost |
$9 |
|
Accreditation |
ACPE |
|
Presenters / Authors / Faculty |
Kevin Schleich, PharmD, BCACP |
|
Keywords / Search Terms |
CEI CEI ce, law, federal, pharmacy, update, legislative, regulatory, pbm, provider status, act |
|